Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 899 of 6351
-
New hope for chinese men with tough prostate cancer: targeted drug takes on standard care
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have…
Phase 4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New balloon treatment may be safer for heart patients prone to bleeding
Disease control OngoingDCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial. The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion in patients with high ble…
Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug shows promise in Late-Stage Sjogren's trial
Disease control CompletedA randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a Triple-Drug cocktail outsmart Treatment-Resistant colorectal cancer?
Disease control Stopped earlyThis Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could a cannabidiol drug help heal inflamed hearts?
Disease control CompletedMulti-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahyd…
Phase 2 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Fasting during chemo: a new way to boost treatment?
Disease control Recruiting nowThis phase II trial studies whether time restricted eating (TRE) works to improve outcomes in patients with stage I-III breast cancer receiving chemotherapy before surgery (neoadjuvant) with a body mass index (BMI) 25-40. TRE has been shown to elicit similar metabolic changes as …
Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Hope for rare immune disease: new drug enters final testing
Disease control Recruiting nowThe primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Brain chip offers hope for untreatable depression
Disease control Recruiting nowChronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull. Over time, intracalvarial cortical stimulation is intermittently activated to modulate locally and distally connect…
Sponsor: Inner Cosmos Inc • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill shows promise for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
Phase 1/2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on childhood brain cancer in first human trial
Disease control OngoingThis is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependym…
Phase 1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a breastfeeding drug mend broken hearts after childbirth?
Disease control Recruiting nowThe study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breas…
Phase 4 • Sponsor: Dennis M. McNamara, MD, MS • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New tailored therapy offers hope for older hodgkin lymphoma patients
Disease control OngoingThis is a multi-center, open-label phase II study to assess the efficacy of a novel fitness-adapted regimen in previously untreated older patients with classical Hodgkin lymphoma. All participants will receive up to a total of 8 cycles of pembrolizumab (Q6 week dosing). The first…
Phase 2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThe purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (prima…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New immunotherapy cocktail shows promise for tough lung cancer
Disease control CompletedThis is an open-label, multi-center, Phase 2 study in subjects with treatment-naïve locally advanced (unresectable and unable to receive radical chemoradiotherapy) or metastatic PD-L1-positive non-small cell lung cancer (NSCLC) who have received systemic therapy.
Phase 2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Ovarian cancer hope: new combo shows promise in shrinking tumors before surgery
Disease control CompletedThe primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combinatio…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Precision freezing targets prostate cancer, spares healthy tissue
Disease control Recruiting nowTo learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Hospital trial aims to stop deadly c. diff before it starts
Prevention Recruiting nowClostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the US. Traditional approaches to reduce hospital-onset CDI focus on identifying, isolating, and treating symptomatic patients t…
Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 09:10 UTC
-
Could a shorter course of blood thinners be safer after a heart attack?
Disease control Recruiting nowThe study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints. In the subgroup of STEMI patien…
Phase 4 • Sponsor: Research Maatschap Cardiologen Rotterdam Zuid • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope in blood cancer battle: Next-Gen drug tested against standard therapy
Disease control Recruiting nowThe purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib m…
Phase 3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC